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The syndrome of periodic fever, aphthous stomatitis, pharyngitis,
and cervical adenitis (PFAPA) is the most common periodic fever
disease in children. However, the pathogenesis is unknown. Using
a systems biology approachweanalyzedblood samples fromPFAPA
patients whose genetic testing excluded hereditary periodic fevers
(HPFs), and from healthy children and pediatric HPF patients. Gene
expression proﬁling could clearly distinguish PFAPA ﬂares from
asymptomatic intervals, HPF ﬂares, and healthy controls. During
PFAPA attacks, complement (C1QB, C2, SERPING1), IL-1–related (IL-
1B, IL-1RN, CASP1, IL18RAP), and IFN-induced (AIM2, IP-10/CXCL10)
genes were signiﬁcantly overexpressed, but T cell-associated tran-
scripts (CD3, CD8B) were down-regulated. On the protein level,
PFAPA ﬂares were accompanied by signiﬁcantly increased serum
levels of chemokines for activated T lymphocytes (IP-10/CXCL10,
MIG/CXCL9), G-CSF, and proinﬂammatory cytokines (IL-18, IL-6).
PFAPA ﬂares also manifested a relative lymphopenia. Activated
CD4+/CD25+ T-lymphocyte counts correlated negatively with serum
concentrations of IP-10/CXCL10, whereas CD4+/HLA-DR+ T lympho-
cyte counts correlated positively with serum concentrations of the
counterregulatory IL-1 receptor antagonist. Based on the evidence
for IL-1β activation in PFAPA ﬂares, we treated ﬁve PFAPA patients
with a recombinant IL-1 receptor antagonist. All patients showed
a prompt clinical and IP-10/CXCL10 response. Our data suggest an
environmentally triggered activation of complement and IL-1β/-18
during PFAPA ﬂares, with induction of Th1-chemokines and sub-
sequent retention of activated T cells in peripheral tissues. IL-1 in-
hibition may thus be beneﬁcial for treatment of PFAPA attacks,
with IP-10/CXCL10 serving as a potential biomarker.
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The syndrome of periodic fever, aphthous stomatitis, pharyn-gitis, and cervical adenitis (PFAPA) represents the most
common autoinﬂammatory fever disorder in childhood (1). This
clinical entity is characterized by regular occurrences of high
fever (>39 °C), which are associated with at least one of the
three cardinal clinical signs, including aphthous stomatitis,
pharyngitis, and cervical adenitis (2, 3). Additional features,
including headache, gastrointestinal symptoms, rash, and ar-
thralgia, may be present (3–6) but are not consistently noted.
The disease onset is generally before the age of 5 y, with attacks
lasting 3 to 6 d and recurring every 3 to 8 wk. Patients are
asymptomatic between episodes and show normal growth and
development. PFAPA usually resolves in adolescence, although
a small but increasing number of patients with adult-onset dis-
ease have been reported (7–9).
The etiology of PFAPA is unknown. Laboratory ﬁndings during
ﬂares show nonspeciﬁc leukocytosis with neutrophilia, elevated
erythrocyte sedimentation rate (3, 4, 6), C-reactive protein (CRP)
(10–12), and ﬁbrinogen (4). In some patients serum IgD can be
elevated (4, 13). PFAPA is diagnosed by exclusion of other
probable causes of recurrent fevers in children, such as infectious,
autoimmune, and malignant diseases. The differential diagnosis
also includes cyclic neutropenia and the hereditary periodic fever
syndromes (HPFs). The latter disorders are caused by genetic
variants of the innate immune system (1) and include familial
Mediterranean fever (FMF), TNF receptor-associated periodic
syndrome (TRAPS), hyperimmunoglobulinemia D with periodic
fever syndrome (HIDS), and cryopyrin-associated periodic syn-
dromes (CAPS). The clinical overlap of PFAPA with these dis-
eases (14–16) requires their exclusion, but at the same time raises
the question of whether PFAPA is a separate entity or whether it
represents a milder manifestation of HPFs or a collection of other
undeﬁned fever syndromes. Proposed concepts of the pathogen-
esis of PFAPA include infection, abnormal host immune re-
sponses, or a combination of both (10, 17).
To date, no completely satisfactory treatment options exist for
PFAPA. Corticosteroid therapy of the ﬂares is often associated
with an increased attack frequency as well as the side effects of
repeated therapy. Adenotonsillectomy is still controversial, per-
haps because of differences in the cohorts that have been studied
(3, 18, 19). Finally, the treatment with cimetidine is only effective
in up to 30% of patients (20). Using a systems biology approach,
we report data, which indicate that PFAPA ﬂares are associated
with an IL-1β/-18–mediated recruitment of activated T cells to
peripheral tissues, implicating Th1-chemokines as potential bio-
markers and IL-1β as a previously unexplored therapeutic target.
Results
Whole-Blood Gene Expression Proﬁling Differentiates PFAPA Flares from
Asymptomatic Intervals and HPF Flares, and Indicates Involvement of
Innate and Adaptive Immunity in the Pathogenesis of PFAPA. From our
prospectively collected cohort of 21 PFAPA patients in whom
HPFs were genetically excluded (Fig. 1A), we performed whole-
blood microarray analysis in paired samples (ﬂare, nonﬂare) of six
patients fulﬁlling stringent PFAPA criteria, as noted in Materials
and Methods, six healthy controls, and six HPF patients sampled
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during ﬂare (Fig. 1B). Unsupervised principal component analysis
of the overall messenger RNA expression revealed that PFAPA
ﬂares were remarkably distinct from asymptomatic intervals in
PFAPA patients, and could be clearly differentiated from ﬂares
of patients with HPFs. In contrast, gene expression in PFAPA
patients during asymptomatic periods was indistinguishable from
that of healthy children (Fig. 2A).
The expression proﬁles of 960 probe sets changed signiﬁcantly
in PFAPA patients when ﬂare and asymptomatic periods were
compared [P < 0.007 at a false-discovery rate (FDR) 2.0%]
(Dataset S1). Among the top up-regulated transcripts during
PFAPA ﬂares were complement genes (Fig. 2B) and transcripts
typically induced by IFN or related to IFN signal transduction
(Fig. 2 C and E). Furthermore, several IL-1– and inﬂammasome-
associated genes showed elevated levels of expression during
PFAPA ﬂares (Fig. 2D). In addition to IFN-inducible protein of
10 kDa (IP-10/CXCL10), which encodes a chemokine for acti-
vated T lymphocytes (21), the transcription of various other
chemokines and chemokine receptors expressed by monocytes
(CCR1, CCR2) was up-regulated, whereas receptors expressed
on T lymphocytes were down-regulated (CXCR3) (Fig. 2E).
Accordingly, a statistically signiﬁcant underrepresentation of a
variety of T-cell–associated transcripts was observed during
PFAPA ﬂares compared with asymptomatic intervals (Fig. 2F).
As these ﬁndings could be simply a reﬂection of changes asso-
ciated with fever during PFAPA, we compared the differential
expression of PFAPA ﬂare-associated transcripts with those seen
during HPF ﬂares. To maximize the possibility of detecting dif-
ferentially expressed genes in this unpaired comparison of patient
samples during fever, we set the fold-change and FDR criteria at
1.5 and 20% (P < 0.03), respectively (Dataset S2). Among a total
of 600 differentially expressed genes, we identiﬁed the following
top ﬁve biological pathways in PFAPA patients: (i) cytotoxic T-
lymphocyte–mediated apoptosis of target cells, (ii) T-cell receptor
signaling, (iii) IL-9 signaling, (iv) p53 signaling, and (v) TREM1
signaling, thereby suggesting the involvement of both adaptive and
innate immunity. We found that 16 of 26 (61%) PFAPA ﬂare-
associated T-cell transcripts differed signiﬁcantly fromHPF ﬂares,
as well as 4 of 7 (57%) IL-1-inﬂammasome–associated genes, 4 of
10 (40%) complement genes, 3 of 10 (30%) chemokine/receptor
genes, and 6 of 25 (24%) IFN-induced genes (Fig. 2 B–F).
The comparison of gene-expression levels between healthy
controls with those of PFAPA patients during asymptomatic
intervals showed no difference at a FDR that would correspond
to a P < 0.05. As these two study populations were indistin-
guishable, we did not compare transcript levels of healthy controls
with PFAPA patients during ﬂares.
To validate our microarray data, we performed quantitative
real-time PCR (qRT-PCR) on a larger group of PFAPA patients
and controls, including PFAPA patients with less stringent
(classic) criteria, as noted inMaterials and Methods (Fig. 1B). We
analyzed 15 paired PFAPA samples (ﬂare, nonﬂare), 11 healthy
controls, and 6 HPF patients during ﬂare. The results of these ex-
periments conﬁrmed the complement, IL-1β– and IFN-activating
processes during PFAPA ﬂares (Fig. S1).
Taken together, our results indicate that gene-expression
levels of asymptomatic PFAPA patients are indistinguishable
from healthy controls, but that transcription patterns during
PFAPA ﬂares involve host defense mechanisms that comprise
innate (complement cascade, IL-1-inﬂammasome) and adaptive
(T lymphocytes, IFN-γ signaling) immunity, and support the idea
of an immunologic response to environmental exposures, possi-
bly infectious, as the trigger of PFAPA ﬂares.
Analysis of Cell Subtype Distributions in Peripheral Blood of PFAPA
Patients Reveals Activation and Peripheral Retention of Th1 Cells
During PFAPA Flares. The concurrent measurement of circulating
white-cell counts and lymphocyte subpopulations during and be-
tween PFAPA ﬂares (Fig. 1B) allowed us to elucidate the cause
of reduced expression of T-lymphocyte–associated mRNA tran-
scripts. During ﬂares, PFAPA patients showed signiﬁcant leu-
kocytosis with neutrophilia and monocytosis, accompanied by
a relative lymphopenia and eosinopenia (Table S1). The PFAPA
ﬂare-associated changes in cell counts also reached statistical
A
Age (yr) - median (IQR) 5.2 (3.6 - 6.7)
Aphthous stomatitis
Pharyngitis
Cervical lymphadenopathy
Abdominal pain
Diarrhea
Nausea/Vomiting
Loss of appetite
Myalgia
Arthralgia
Rash
Pleurisy
Ocular
13 (62)
18 (86)
21 (100)
12 (57)
  2 (10)
  8 (38)
20 (95)
12 (57)
  6 (29)
  2 (10)
  1 (5)
  1 (5)
1.1 (0.6 - 3.4)Age at onset (yr) - median (IQR) 
Sex - number (%)  
  Female 8 (38)
  Male 13 (62)
Ethnicity - number (%) 
  Caucasian 21 (100)
Clinical Features of Attacks
Duration (d) - median (IQR) 4.5 (3.2 - 5)
Frequency (d) - median (IQR) 28 (22.7 - 29.5)
Maximum temperature - oC (IQR) 40.8 (40.6 - 41.1)
Value
Demographic
Associated Features with Fever – number (%)
Characteristic
B
N=12
(flare samples)
N=21
(paired samples:
non-flare and flare) 
N=21
HPF patientsPFAPA patientsHealthy controls
Microarray analysis
2 FMF - M694V/E148Q and M694Vdel in MEFV
2 TRAPS - C52G and C72R in TNFRSF1A 
3 HIDS - V377I/G171R and 2 V377I/I268T in MVK
4 CAPS - 2 G569R, V262A, and L632F in CIAS1
1PAPA - E250Q in PSTPIP1
Study population
Controls     PFAPA     HPFs
    N=6          N=6         N=6
HPFs
N=6
PFAPA
Complete blood cell count
C-reactive protein Infectious serology / ANALymphocyte phenotyping 
Serum cytokines/chemokines Complement activity
Stringent PFAPA
criteria
9 PFAPA
5 Controls
2 PFAPA
3 HPFs
qRT- PCR
6 PFAPA
Classic
PFAPA
criteria 
Controls     PFAPA     HPFs
    N=11       N=15        N=6
Controls      PFAPA       HPFs
  N=21        N=19-20     N=9-10
Controls      PFAPA       HPFs
  N=21        N=16-19       ND
Controls      PFAPA       HPFs
  N=21        N=19-21      N=11
Controls      PFAPA       HPFs
    ND            N=21          ND
Controls       PFAPA      HPFs
N=19-20        N=17        N=12
Controls      PFAPA     HPFs
    ND           N=7-8       N=8
Fig. 1. Study population and procedures. (A) Demographic and clinical characteristics of 21 patients with PFAPA syndrome. IQR, interquartile range. (B)
Schematic of the overall study population and number of patients analyzed in each different assay or experiment. Deﬁnitions of classic and stringent PFAPA
criteria are provided in Materials and Methods. Infectious serology comprised antistreptolysin O, anti-DNaseB, antibody titers against HSV 1 and 2, EBV, and
CMV. ANA, anti-nuclear antibody; ND, not done; PAPA, pyogenic arthritis, pyoderma gangrenosum, and acne syndrome.
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signiﬁcance for lymphocytes, monocytes, and eosinophils, com-
pared with HPF patient results during ﬂares.
Lymphocyte immunophenotyping showed that T lymphocytes
were signiﬁcantly reduced during PFAPA ﬂares compared with
asymptomatic intervals, affecting both CD4+ and CD8+ T-cell
numbers (Table S1). Of these populations, activated CD4+ T
cells, identiﬁed as CD4+HLA-DR+ (P= 0.03) and CD4+CD25+
(P = 0.004), were signiﬁcantly reduced during attacks, whereas
activated CD8+ T cells did not differ. Although double-negative
CD3+ lymphocytes were signiﬁcantly lower during PFAPA ﬂares,
there was no difference compared with healthy controls. The γ/δ
T lymphocytes were slightly increased during asymptomatic peri-
ods of PFAPA relative to healthy controls, but did not show
any change during ﬂares. There were no differences in numbers of
B cells, natural killer cells, and natural killer T cells when com-
paring PFAPA patients during ﬂare and symptomatic periods or
in healthy controls. In summary, these data indicate that in ad-
dition to the well-recognized neutrophilia, numbers of mono-
cytes, eosinophils, and activated CD4+ lymphocytes are markedly
perturbed during PFAPA attacks.
PFAPA Flares Are Associated with High Serum Levels of Pro-
inﬂammatory Cytokines and Th1-Chemokines. To understand the
basis for the cellular distributions during ﬂares in the context of
our gene-expression results, we measured IP-10/CXCL10, in ad-
dition to 27 other chemokines and cytokines, as markers of cel-
lular activation in sera of PFAPA patients, healthy controls, and
HPF ﬂare patients (Fig. 1B). Three chemokines [IP-10/CXCL10,
monokine induced by IFN-γ (MIG/CXCL9), and macrophage
inﬂammatory protein 1β (MIP-1β/CCL4)] that are known T-cell
chemoattractants were signiﬁcantly elevated during PFAPA
ﬂares compared with asymptomatic intervals (Fig. 3A), as were
the levels of three proinﬂammatory cytokines (IL-18, IL-6, and
G-CSF). In addition, IL-1–receptor (IL-1R) antagonist showed
a marked increase during PFAPA ﬂares that reached statistical
signiﬁcance in comparison with healthy children (P < 0.001), but
not compared with asymptomatic PFAPA periods (Fig. 3A).
Comparing chemokine and cytokine values during PFAPA and
HPF ﬂares, we found that IP-10/CXCL10, MIG/CXCL9, MIP-1β,
IL-1R) antagonist, and G-CSF were signiﬁcantly higher with
PFAPA ﬂares. During their asymptomatic intervals, PFAPA
patients showed slightly, but signiﬁcantly elevated levels of MIG/
CXCL9, MIP-1β, IL-6, and G-CSF relative to healthy controls
(Fig. 3A). CRP levels increased signiﬁcantly during PFAPA epi-
sodes, but reached levels similar to those seen during HPF ﬂares
(Fig. 3B).
Given the highly elevated gene-expression levels of a variety of
complement components during PFAPA ﬂares, we next analyzed
the functional activity of the classical (CH50) and alternative
pathway (AH50), as well as serum and plasma components, as
potential indicators of environmental PFAPA triggers. PFAPA
ﬂares were associated with a marked increase of CH50 activity,
which almost reached statistical signiﬁcance (P = 0.06) in com-
parison with asymptomatic PFAPA intervals, whereas there was
no change in AH50 activity (Fig. S2). Properdin Factor B, a
component of the alternative pathway but also an acute-phase
reactant, was signiﬁcantly elevated during PFAPA ﬂares relative
to asymptomatic intervals (P = 0.04), but did not differ from the
elevated values during HPF ﬂares. Measurements of serum C1-
INH, C1q, C2, C3, C4, and C5 in two PFAPA patients during
ﬂares were normal (Dataset S3). Plasma levels of the activated
complement fragments Bb, C3a, C4D, and C5a were within nor-
mal ranges when measured in one PFAPA patient during a ﬂare.
Because the classic complement pathway is activated via
antigen-antibody complexes, as well as a variety of bacterial and
viral agents, we analyzed antinuclear antibody and serum titers
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IFIT5
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MX1
TAP2
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Non-Flare 
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 Flare 
HPF - 
Flare 
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Non-Flare 
PFAPA - 
  Flare 
HPF - 
Flare 
PFAPA - 
Non-Flare 
PFAPA - 
  Flare 
HPF - 
Flare 
*
*
*
*
Complement - associated genes
SERPING1
C2
C1QB
C1QA
CD59
CR1
C3AR1
C1RL
CD46
CFB
IL-1β and inflammasome-associated genes
Log2 (expression ratio)
Log2 (expression ratio)
Log2 (expression ratio)
Controls PFAPA - 
Non-Flare 
PFAPA - 
  Flare 
HPF - 
Flare 
Log2 (expression ratio)
PFAPA Non-Flare        Control
PFAPA Flare                Non-PFAPA Flare     
PCA Mapping
A
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F
Fig. 2. Distinct whole-blood gene expression proﬁles in PFAPA syndrome. Microarray analysis of messenger RNA extracted from whole blood of six PFAPA
patients during and between episodes, six healthy controls and six hereditary periodic fever patients during ﬂares [two FMF (M694V/E148Q and M694del in
MEFV), one TRAPS (C52G in TNFRSF1A), three CAPS (two G569R, and L632F in NLRP3/CIAS1)]. (A) Principal component analysis of differentially expressed
genes, with each dot representing one subject. (B–F) Hierarchical clustering of differentially expressed genes in the four study groups, with genes selected and
listed according to their intensity of expression and canonical pathways, respectively. Gene symbols are depicted in the left column. At least twofold and
statistically signiﬁcant differences of probe set expression between active and inactive PFAPA disease states are shown (Wilcoxon signed-rank test P < 0.007,
FDR 2%). Asterisks in the right column indicate at least 1.5-fold signiﬁcantly changed transcript levels when comparing ﬂares of PFAPA with ﬂares of he-
reditary autoinﬂammatory diseases (Mann-Whitney U test P < 0.03, FDR 20%). Expression values were normalized per gene (row) to the mean of the healthy
control group; each column represents one individual. As shown on the color bars, red indicates relative up-regulation, blue relative down-regulation.
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against microbial pathogens (Fig. 1B). However, these results
were not indicative for an autoimmune disease or concurrent in-
fection (SI Results).
IP-10/CXCL10, MIG/CXCL9, and G-CSF Are Potential Biomarkers for
IL-1/-18–Driven PFAPA Flares. To identify cytokines/chemokines
that could best classify PFAPA ﬂares and therefore serve as
potential biomarkers, we ﬁrst examined correlations among the
quantitative traits (peripheral leukocyte subsets, serum chemo-
kines/cytokines) that were signiﬁcantly elevated during PFAPA
attacks across patients (n = 17). Increased IP-10/CXCL10 levels
correlated strongly with a decrease of circulating CD4+CD25+
lymphocytes (r = −0.83, P < 0.001), and an increase of MIG/
CXCL9 (r = 0.64, P = 0.006) and G-CSF (r = 0.51, P = 0.04)
(Dataset S4). MIG/CXCL9, which is chemotactic for lympho-
cytes and eosinophils, correlated negatively with peripheral eo-
sinophil counts (r = −0.58, P = 0.03), and showed a strong
association with IL-18 (r = 0.63, P = 0.007). Serum concen-
trations of IL-1R antagonist were signiﬁcantly correlated with
CD4+HLA-DR+ lymphocytes (r = 0.59, P = 0.03). Further-
more, we found high correlations between concentrations of
CRP and the T-cell recruiting chemokines, IP-10/CXCL10 (r =
0.64, P = 0.008) and MIG/CXCL9 (r = 0.74, P = 0.002).
To identify the strongest independent correlates of PFAPA
ﬂares among the signiﬁcantly elevated serum cytokines/chemo-
kines, we then used multivariate logistic regression models. As
the serum IL-1R antagonist levels were not normally distributed,
even with transformations, we excluded this variable from these
calculations. PFAPA ﬂares were independently associated with
increased serum levels of IP-10/CXCL10, MIG/CXCL9, and G-
CSF (Dataset S5). Furthermore, the signiﬁcant association of
serum IL-18 levels with PFAPA ﬂare was linked to these three
chemokines/cytokines (Dataset S5).
To analyze the interrelations of the signiﬁcant ﬂare correlates
with each other and the three additional ﬂare-associated che-
mokines/cytokines (MIP-1β, IL-18, IL-6), we tested associations
between changes in levels of these chemokines/cytokines within
each patient between ﬂare and asymptomatic periods using
multivariate linear regression. Overall, changes in IP-10/CXCL10
and MIG/CXCL9 between ﬂare and nonﬂare states were closely
associated with changes in G-CSF, independent of the other
variables for which we adjusted (Dataset S6). Changes of IL-18
were closely related to changes in MIG/CXCL9, but less closely
related to changes in IP-10/CXCL10 and G-CSF.
IL-1 Blockade Resolves PFAPA Flares and IP-10/CXCL10 Response.
Given the overexpression of inﬂammasome-related genes in
PFAPA ﬂares, we hypothesized that PFAPA patients might
beneﬁt from IL-1 inhibition. Five consecutively recruited PFAPA
patients fulﬁlling classic PFAPA criteria (Fig. 4A) received one
dose of the recombinant IL-1R antagonist, anakinra, each on the
second day of the ﬂares. All children showed a prompt clinical
response, with their fevers and inﬂammatory symptoms ceasing
within hours of the injection (Fig. 4B). Two patients had a fever
relapse 1 d (patient 4) and 2 d (patient 2) after treatment, re-
spectively, whereas the other three patients remained afebrile.
Patient 4 was administered a second dose of anakinra 24 h fol-
lowing the ﬁrst dose and showed, again, a rapid decline of his
fever. Leukocyte count and CRP declined 48 h after anakinra.
Serum IP-10/CXCL10 concentrations, elevated before anakinra,
greatly diminished by 24 h after treatment (Fig. 4C). Levels of
MIG/CXCL9 and G-CSF were markedly elevated in four and
three patients, respectively, and declined continuously after
treatment, but IL-18 concentrations were unchanged in four of
the ﬁve patients (Fig. S3). Adverse events were limited to one
episode of vomiting immediately after injection in one patient.
Discussion
In this article, we used a comprehensive systems biology approach
to study PFAPA, a common but poorly understood recurrent
fever syndrome in children. Our data draw important distinctions
between PFAPA and the HPFs at the level of gene expression and
serum cytokines, suggesting biomarkers that may help to clarify
the diagnosis and informing our understanding of the patho-
physiology of disease ﬂares. Molecules of the innate immune
system, such as complement, IL-1β, and G-CSF, appear to ﬁgure
prominently in PFAPA attacks, and several lines of evidence
suggest an important effector function for activated CD-4+ T
lymphocytes. Favorable clinical and laboratory responses to
anakinra place IL-1β proximal in the attack cascade and suggest
a previously unexplored treatment option for PFAPA.
Clinical overlap with HPFs and the lack of speciﬁc laboratory
markers require the exclusion of other causes of recurrent fevers
before making the diagnosis of PFAPA, which is often associated
with a multitude of costly hospital admissions. Our data corrob-
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Fig. 3. Distinct inﬂammatory protein measures in PFAPA patients. Values of (A) serum cytokines and chemokines and (B) CRP in PFAPA patients during and
between ﬂares, healthy controls, and HPF patients during ﬂare. Results for IL-1β, IL-2, IL-4, IL-5, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17, Eotaxin, FGF basic,
GM-CSF, IFN-γ, MCP-1, MIP-1α, PDGF BB, RANTES (regulated upon activation, normal T cell-expressed and -secreted), TNF-α, and VEGF did not show any
statistically signiﬁcant differences in any of the comparisons and therefore are not shown. NS, not signiﬁcant.
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orate the concept of PFAPA as a distinct nosologic entity, which
can be differentiated on the basis of gene expression and protein
levels when comparing attacks with asymptomatic intervals, as
well as with ﬂares of HPF patients. The latter distinction helps to
establish the PFAPA gene-expression proﬁle as different from
a more nonspeciﬁc fever-associated signature.
Although PFAPA is the most common and clinically well-de-
ﬁned periodic fever syndrome in children, a unifying pathophys-
iologic concept of this disease is lacking. Our data support a
model of PFAPA in which environmental exposures and pos-
sible immunologic variants in the immature host conspire to cause
recurrent febrile episodes (Fig. S4) (10, 17). PFAPA ﬂares are by
deﬁnition not associated with documented upper respiratory tract
infection and—except for anecdotal reports of pathogen isolation
from tonsillar or adenoidal tissues (2, 22)—no infectious pro-
cesses have been identiﬁed so far. However, our ﬁndings of
marked induction of genes encoding numerous innate immune
molecules, including both structural and counter regulatory
complement proteins, during PFAPA ﬂares, taken together with
the cardinal ﬁndings of oral and pharyngeal inﬂammation and
cervical adenopathy, strongly suggest a microbial trigger, perhaps
ampliﬁed in the susceptible host at a particular stage of de-
velopment. Although the overexpression of complement genes
has also been described in children with systemic onset juvenile
idiopathic arthritis (SoJIA), an autoinﬂammatory disease with
a complex genetic etiology (23, 24), the intensity of up-regulation
was comparable to the results of our HPF group, therefore sug-
gesting a nonspeciﬁc activation in SoJIA. Given the lability of
complement proteins (25), it is not surprising that only one report
of elevated serum complement C3 levels in PFAPA has been
published (26). To better understand the trigger mechanism in
PFAPA, future comparison of gene-expression proﬁles from
PFAPA patients during ﬂares with those of patients with other
febrile illnesses should provide further information and insight as
to why the immune system is stimulated with periodicity.
PFAPA ﬂares were also characterized by evidence, at both
the mRNA and protein level, of IL-1β and IL-18 activation, a
further component of the innate immune system. The initiation of
IL-1β and IL-18 processing is inﬂammasome-mediated. Inﬂam-
masomes are cytoplasmic macromolecular protein complexes that
control the activation of caspase-1, which cleaves pro-IL-1β and
pro-IL-18 into the biologically active, secreted forms (27). The
increased expression of AIM2 and caspase-1 transcripts during
ﬂares of our PFAPA patients suggests activation of the AIM2
inﬂammasome (28–30), and thereby adds to the growing body of
data implicating the role of IL-1β activation in periodic fever
syndromes (1).
IL-1β acts as costimulator of T-cell function, usually together
with an antigen ormitogen (31).Our ﬁndings correlating serum IL-
1R antagonist levels (a surrogate for IL-1 levels, which are difﬁcult
to assay because of binding proteins in the serum) with activated
CD4+HLA-DR+ lymphocytes support this mechanism of T lym-
phocyte stimulation following monocyte/macrophage activation
during PFAPA ﬂares. Activated T cells secrete IFN-γ, thereby
enhancing monocyte/macrophage stimulation via a feedback loop.
Accordingly, we found highly elevated serum levels of IFN-
inducible chemokines, IP-10/CXCL10 andMIG/CXCL9, as well as
G-CSF, a neutrophil-inducing cytokine. IP-10/CXCL10 and MIG/
CXCL9 are secreted by monocytes and neutrophils, and belong to
the same chemokine family that recruits activated T lymphocytes
via the receptor CXCR3 (21). The strong inverse correlation of IP-
10/CXCL10 with CD4+CD25+ T cells during ﬂares of our PFAPA
patients, along with a relative lymphopenia, argue for recruitment
of activated T lymphocytes to inﬂamed peripheral tissues, as lymph
nodes and adenoids. Neither gene-expression studies of TRAPS-
associated TNFRSF1A mutations in an endothelial cell line (32),
nor of peripheral blood mononuclear cells of SoJIA patients (33,
34), implicated these T cell-recruiting chemokines. Thus, mea-
surement of serumTh1 chemokines could provide a novel basis for
diagnostic testing of PFAPA that would be especially useful in
a setting without access to genetic exclusion of HPFs.
Based on this conceptual formulation, which would place IL-1β
upstream of T-cell activation in PFAPA, we treated ﬁve PFAPA
patients during an attack with recombinant IL-1R antagonist. All
patients showed a prompt clinical response, accompanied by
a rapid decline of serum IP-10/CXCL10 and MIG/CXCL9, thus
supporting a model in which IL-1β drives Th1 chemokines. Serum
levels of IL-18, which acts upstream of the IL-1R antagonist,
slightly increased. The fact that two patients had a fever relapse
following anakinra injection is not surprising, given the short half-
life of the medication. When we administered two doses of ana-
kinra in one patient, the episode was shortened to half the regular
Fig. 4. Clinical and laboratory response of PFAPA patients treated with recombinant IL-1R antagonist (anakinra). Subcutaneous injection of ﬁve PFAPA
patients with one dose of the recombinant IL-1R antagonist (anakinra) each, between 21 and 48 h following the onset of ﬂare; one patient (patient 4)
received an additional dose of recombinant IL-1R antagonist (anakinra) 24 h after the ﬁrst dose. (A) Summary of demographic and clinical data of the ﬁve
PFAPA patients; *Patient 5 received daily cimetidine but continued to have classic ﬂares. (B) Fever curves before and after treatment; red arrows indicate
injection of recombinant IL-1R antagonist (anakinra), black arrows indicate administration of ibuprofen, gray arrow indicates administration of acetamin-
ophen. (C) Laboratory values and cytokine/chemokine measurements in sera before and after injection of recombinant IL-1R (anakinra).
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duration. Given the fact that many patients experience an in-
creased frequency of attacks following steroids (5, 6), and that
adenotonsillectomy is an invasive and therefore risk-associated
procedure, our results support IL-1 inhibition as an alternative
treatment option of PFAPA attacks. Future randomized treat-
ment trials of PFAPA patients will help to determine efﬁcacy and
safety of anakinra, which so far has been well tolerated when
administered daily in CAPS patients (35, 36).
In summary, a multiparameter analytic approach clearly dif-
ferentiates ﬂares of PFAPA from exacerbations of the HPFs. Key
features of PFAPA attacks include complement and IL-1β/-18 ac-
tivation, an IFN gene signature, Th1-chemokinemia, and marked
reductions in circulating activated CD4+ T cells and eosinophils.
We propose a model in which microbial triggers activate a cascade
that begins with the innate immune system and ultimately recruits
activated T cells to the periphery. Because the immunologically
immature host appears to play at least a permissive role, longitu-
dinal studies of patients with PFAPA may provide additional
insights into the ontogeny of how these pathways are regulated. The
ﬁndings reported here may also provide the basis both for the
improved diagnosis and treatment of PFAPA.
Materials and Methods
PFAPA Patients. Patients less than 18 y of age with a diagnosis of PFAPA
fulﬁlled the following classical criteria: (i) recurrent fever episodes (>38.5 °C)
with aphthous stomatitis or pharyngitis or cervical lymphadenitis; (ii) ex-
clusion of infectious, rheumatic, and autoimmune disorders, immunodeﬁ-
ciency, and cyclic neutropenia (exclusion of mutations in the ELA2 gene); (iii)
exclusion of the hereditary periodic fever syndromes FMF, TRAPS, HIDS, and
CAPS; and (iv) no treatment with systemic corticosteroids 10 d before en-
rollment, and no treatment with cimetidine, colchicine, montelukast or im-
mune response modulators 3 mo before enrollment.
We analyzed bymicroarray whole-blood samples obtained from six PFAPA
patients (three females, three males; median age 5.6 y, range 2.8–9.7) who
fulﬁlled—in addition to our study inclusion criteria—the following stringent
PFAPA requirements: (i) fever episodes associated with at least two of the
classic clinical features, (ii) leukocytosis with neutrophilia or elevated CRP
during the ﬂare, and (iii) no clinical or laboratory signs of inﬂammation
during the asymptomatic interval of blood sampling.
During an attack, administration of nonsteroidal anti-inﬂammatory drugs,
such as acetaminophen or ibuprofen, was not permitted within 24 h, nap-
roxen within 48 h, and steroids at no time point before specimen sampling,
except in the case of the ﬁve patients who also received anakinra and were
allowed to take acetaminophen or ibuprofen. We aimed to collect blood
samples from each PFAPA patient when asymptomatic and within 48 h
following the onset of an attack.
Collection and Analysis of Blood Samples. A detailed description of the
materials and methods used for DNA sequence analysis, microarray analysis,
real-time quantitative RT-PCR, cytokine and chemokine measurements,
lymphocyte immunophenotyping, complement system analyses, and statis-
tical analyses is provided in SI Materials and Methods.
Treatment with IL-1R Blockade. After parental informed consent, ﬁve PFAPA
patients received anakinra, a recombinant human IL-1R antagonist, at 1 mg
per kilogram body weight once subcutaneously within 48 h following the
onset of an attack. One patient received a second dose 24 h after the initial
dose. Patients were monitored clinically for 24 to 48 h after the injection.
Blood samples were collected immediately before treatment and 24 h after
therapy in all subjects, with some patients also providing samples at 48 h.
Complete blood cell counts, CRP, serum IP-10/CXCL10, MIG/CXCL9, G-CSF, IL-
18, IL-6, and MIP-1β were measured on all available samples.
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